Axsome Therapeutics Inc (AXSM)

[BioSpecialist]

5 Top Biotech Penny Stocks to Buy with Huge Catalysts in January 2018...December 21, 2017

https://moneymorning.com/2017/12/21/5-top-biotech-penny-stocks-to-buy-with-huge-catalysts-in-january-2018/

Currently trading at $4.85, Manhattan-based Axsome Therapeutics Inc. (Nasdaq: AXSM) makes drugs to treat depression, Alzheimer's disease, and chronic pain.

Unlike other biotech penny stocks, shares of AXSM aren't "all in" on just one drug's results.

Axsome has at least three different drugs in clinical trial testing, meaning it has a greater chance of having at least one of its drugs pass. This makes shares of AXSM less risky than a biotech penny stock with only one drug in development.

Specifically, we're going to focus on Axsome's AXS-02 drug, which is in two separate phase 3 clinical trials to treat complex regional pain syndrome and knee osteoarthritis associated with bone marrow lesions. The results for these two clinical trials are expected in late December or early January.

If the AXS-02 drug passes phase 3 clinical trials, the stock could jump significantly.

The company also has a second drug, AXS-05, currently in phase 3 clinical trials for the treatment of treatment-resistant depression. Those results are expected sometime in the first half of 2018, so it's likely that AXS-02's results will come out first.

The next company we'll show you is the cheapest on this list…